{
  "id": "5e44b04c48dab47f26000016",
  "type": "factoid",
  "question": "Which receptor is inhibited by bimagrumab?",
  "ideal_answer": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27167138",
    "http://www.ncbi.nlm.nih.gov/pubmed/25381300",
    "http://www.ncbi.nlm.nih.gov/pubmed/24298022",
    "http://www.ncbi.nlm.nih.gov/pubmed/29226558",
    "http://www.ncbi.nlm.nih.gov/pubmed/31761834",
    "http://www.ncbi.nlm.nih.gov/pubmed/26506009",
    "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
    "http://www.ncbi.nlm.nih.gov/pubmed/27462398",
    "http://www.ncbi.nlm.nih.gov/pubmed/28905498",
    "http://www.ncbi.nlm.nih.gov/pubmed/30095981"
  ],
  "snippets": [
    {
      "text": "Bimagrumab is a human anti-ActRII antibody which was found to increase muscle mass and function by blocking ActRII signaling",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29226558",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Bimagrumab alters the function of pituitary gonadotroph cells, consistent with blockade of activin on local ActRII. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE: Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30095981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Blocking the action of negative muscle regulators through the activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30095981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to explore the clinical potential of bimagrumab, a human monoclonal antibody targeting the activin type II receptor, for the recovery of skeletal muscle volume from disuse atrophy using an experimental model of lower extremity immobilization.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors (ActRII).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nBimagrumab is a human monoclonal antibody inhibitor of activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE\n\nBimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30095981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CDD866 (murinized version of bimagrumab) is a neutralizing antibody against the activin receptor type II (ActRII) preventing binding of ligands such as myostatin and activin A, which are involved in cancer cachexia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27462398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have developed a novel , human anti-ActRII antibody ( bimagrumab , or BYM338 ) to prevent binding of ligands to the receptors and thus inhibit downstream signaling",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24298022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to explore the clinical potential of bimagrumab , a human monoclonal antibody targeting the activin type II receptor , for the recovery of skeletal muscle volume from disuse atrophy using an experimental model of lower extremity immobilization",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle growth",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Novel antiresorptive and anabolic therapies are emerging for osteoporosis as well as drugs for sarcopenia , cancer cachexia or muscle wasting disorders , including antibodies against myostatin or activin receptor type IIA and IIB ( e.g. bimagrumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26506009",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A global , randomized , double-blind placebo-controlled study was conducted to confirm that BYM338 ( bimagrumab) , an anti-activin type II receptor antibody , improves motor function in patients with sporadic inclusion body myositis after 52 weeks' treatment consisting of intravenous administration every 4 weeks at doses of 10 , 3 , and 1 mg/kg",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761834",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab ( BYM338 ) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors ( ActRII",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors (ActRII).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27167138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nBimagrumab is a human monoclonal antibody inhibitor of activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab also blocks other endogenous ActRII ligands, such as activins, which act on the neurohormonal axes, pituitary, gonads and adrenal glands.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE\nBimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30095981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab also blocks other endogenous ActRII ligands, such as activins, which act on the neurohormonal axes, pituitary, gonads and adrenal glands.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24298022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30095981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Blocking the action of negative muscle regulators through the activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30095981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to explore the clinical potential of bimagrumab, a human monoclonal antibody targeting the activin type II receptor, for the recovery of skeletal muscle volume from disuse atrophy using an experimental model of lower extremity immobilization.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CDD866 (murinized version of bimagrumab) is a neutralizing antibody against the activin receptor type II (ActRII) preventing binding of ligands such as myostatin and activin A, which are involved in cancer cachexia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27462398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested inhibition of activin receptors IIA and IIB (ActRII) in 14 patients with sIBM using one dose of bimagrumab (n = 11) or placebo (n = 3).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25381300",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "activin type II receptors"
}